Overview

Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer

Status:
Not yet recruiting

Trial end date:
2030-01-01

Target enrollment:

Participant gender:

Summary

This is an international, multicenter, randomized, open, Phase III trial to evaluate the efficacy and safety of carboplatin/paclitaxel/bevacizumab followed by bevacizumab and niraparib compared to carboplatin/paclitaxel followed by niraparib in patients with newly diagnosed advanced ovarian cancer.

Phase:

Phase 3

Details

Lead Sponsor:

AGO Study Group

Collaborator:

European Network of Gynaecological Oncological Trial Groups (ENGOT)

Treatments:

Bevacizumab
Carboplatin
Niraparib
Paclitaxel